nach oben

Erschienen in:

01.07.2021 | News item

Revisions of precautions and ADRs for monoclonal antibodies

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has published revisions of precautions and/or adverse drug reactions required on the package inserts of three monoclonal antibodies: ixekinumab, pembrolizumab and nivolumab genetic recombinations.¹^,²^,³ …

1. Pharmaceuticals and Medical Devices Agency. Revision of Precautions Internet Document : 15 Jun 2021. Available from: URL: https://www.pmda.go.jp/files/000241101.pdf

2. Pharmaceuticals and Medical Devices Agency. Revision of Precautions Internet Document : 15 Jun 2021. Available from: URL: https://www.pmda.go.jp/files/000241102.pdf

3. Pharmaceuticals and Medical Devices Agency. Revision of Precautions - Nivolumab (genetical recombination) Internet Document : 21 Jun 2021. Available from: URL: https://www.pmda.go.jp/files/000241217.pdf

Titel: Revisions of precautions and ADRs for monoclonal antibodies
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-98123-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Cisatracurium besilate

Multiple drugs

Isoprenaline

Ticagrelor

Multiple drugs

Acitretin/ciclosporin/corticosteroids